Due to its dual mechanism of action, NDC-1308 is being developed as a therapeutic platform drug to treat specific neurodegenerative diseases that are caused by inflammation and/or demyelination.
NDC-1308: A DUAL MECHANISM OF ACTION
Directly Polarizes Macrophages to M2-like State
NDC-1308 upregulates the Lipoprotein Lipase (LPL) gene and functional protein expression within CNS macrophages which polarizes macrophages to the M2-like state (pro-repair, anti-inflammatory).
Directly Induces OPC Differentiation
NDC-1308 upregulates key genes within Oligodendrocyte Progenitor Cells (OPC) that induce OPC to differentiate into mature, myelinating Oligodendrocytes.